baber/WOPTO huggingface dataset:
Patent FI-953332-A0 (FI)
Inventor: GERHARDT KLAUS
IPC: B27N3/18
Filed: 1995-07-06
Abstract: The preheating process is carried out by a climatized fluid of air and water vapour. The fluid passes through the dispersant material, and is at a temperature, which is higher than the dew point by the dew point differential. Fluid volume, dew point, and dew point differential are chosen, so that the prechosen preheating temperature for the dispersant is achieved. There may be some condensation in the dispersant. The humidity of the warmed dispersant can be adjusted by additional processes. The fluid temperature is below 100x, and the fluid has a relative humidity of approx. 30%.
Patent FI-964284-A0 (FI)
Inventor: POIRIER JUDES
IPC: C12Q1/68
Filed: 1996-10-24
Abstract: PCT No. PCT/CA95/00240 Sec. 371 Date Feb. 21, 1997 Sec. 102(e) Date Feb. 21, 1997 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/29257 PCT Pub. Date Nov. 2, 1995The present invention relates to a method for the identification of human subjects to be responsive to cholinomimetic therapy comprising determining the absence of apolipoprotein E4 (apoE4) alleles in a biological sample of the patient where the absence of at least one apoE4 allele indicates a predisposition to respond to cholinomimetic therapy and methods of administering cholinomimetics to such identified subjects.
Patent FI-972795-A0 (FI)
Inventor: HIRATA MITSUTERU
IPC: C07D239/69
Filed: 1997-06-27
Abstract: The present invention is directed to a pyrimidine derivative of the following formula (1) or a salt of the derivative: <CHEM> Äwherein R<1> represents a lower alkyl group; each of R<2> and R<3> represents H, alkyl, or alkoxy; each of R<4> and R<5> represents H or alkyl; R<6> represents alkyl, -OR<7>, or -NR<8>R<9>; and n is a number between 0 and 3 inclusive (wherein each of R<7>, R<8>, and R<9> represents H, alkyl, aryl, aralkyl, amino, a heterocyclic ring, etc.)Ü, as well as to a medicine containing the derivative or salt as the active ingredient. The present compounds exhibit strong binding inhibitory activity against endothelin having potent vasoconstrictive effect and cell proliferation effect. Therefore, the compounds are effective as remedies for various diseases including circulatory diseases.
Patent AP-9701125-A0 (AP)
Title: Nicotinic agents in addiction therapy.
Inventor: O'NEIL BRIAN THOMAS
IPC: A61P25/34
Filed: 1997-10-23
Abstract: Pyridone-fused azabicyclic compounds of the formula (i)and their pharmaceutically acceptable salts and prodrugs, wherein r1, r2 and r3 are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula i in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, huntington's chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia, analgesia, attenion deficit disorder (add). Multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile demenia of the alzheimer's type, parkinson's disease, attention deficit hyperactivity disoder (adhd), aniety, obesity, tourette's syndrome and ulcerative colitis.
Patent IL-66695-A0 (IL)
Title: Acaricidal compositions comprising certain hydroquinone diethers and a synergist
IPC: A01N31/16
Filed: 1982-09-01
Abstract: Acaricide mixtures obtained from the synergistic coupling of an acaricide belonging to the class of the hydroquinone diethers with metallic copper or copper compounds and the use of said mixtures in suitable compositions in the treatment of mite infestations on useful plants are disclosed.
Patent IL-81319-A0 (IL)
Title: Preparation of alpha-amino-alpha-hydrogen carboxylic acid amides
IPC: C07D233/61
Filed: 1987-01-20
Abstract: The invention relates to a process for the preparation of  alpha -amino- alpha -hydrogen carboxylic acid amides of the formula <CHEM> where R1 represents alkyl, alkaryl, aryl, alkenyl, heteroalkyl or heteroaryl, whether or not substituted, by conversion of the corresponding amino nitriles and is characterized in that the conversion takes place in the presence of hydrogen peroxide and ammonia. By preference use is made of 2-6 moles hydrogen peroxide and 3-12 moles ammonia per mole  alpha -amino nitrile.
Patent IL-83259-A0 (IL)
Title: Disposable cell and diaphragm pump for use of same
IPC: F04B43/02
Filed: 1987-07-20
Abstract: A disposable cell for a diaphragm-actuated fluid-transfer control device, which comprises two cell walls (2,4) peripherally joined (22) to one another, of which at least one wall (2) is flexible, and is adapted to be flexed from a first position, in which it is located in close proximity to the other wall (4), reducing the space enclosed between the two walls (2,4) to a minimum, to at least a second position, in which at least some regions of the flexible wall have moved away from the other wall, thereby increasing the space between the two walls (2,4), and an inlet port (10)and an outlet port (16) provided in at least one of the walls (2,4). There is also described a combination of a disposable cell with a diaphragm-actuated fluid transfer control device.
Patent IL-91816-A0 (IL)
Title: Hydroponic crop production
IPC: A01G31/00
Filed: 1989-09-28
Abstract: Hydroponic substrates are disinfected in situ, prior to a crop production cycle, with a dilute aqueous solution containing hydrogen peroxide and at least one peracid having a <CHEM> r
Patent AU-PN627595-A0 (AU)
Title: Diagnostics and treatments of periodontal disease
IPC: A61K39/00
Filed: 1995-10-30
Abstract: This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell association protein complex comprising the PrtR and PrtK proteins. Accordingly the invention provides a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.
Patent FI-20000921-A0 (FI)
Inventor: POHJANEN PETRI
IPC: H04N5/00
Filed: 2000-04-17
Abstract: The present invention relates to a method for controlling the reception of a digital transmission and for receiving the additional information relating to a digital transmission into the terminal device (MS), in which method the provider of the digital transmission (TV) sends digital information to the receiving equipment and which digital information is displayed on the receiving equipment (STB) or on some other device attached to it.  In the method in accordance with the invention, the decoding key entitling to the decoding of the digital transmission is transmitted to the terminal device (MS); the decoding key entitling to the decoding of the digital transmission is transferred to the receiving equipment (STB); and the digital transmission received is decoded with the aforementioned decoding key.
Patent FI-20055574-A0 (FI)
IPC: D21F9/00
Filed: 2005-10-26
Abstract: A web-forming section of a paper or board machine has a first web-forming unit with a first fiber layer (W1) formed on a first wire (10); a second web-forming unit with a second fiber layer (W2) formed on a second wire (30); and a couch shoe (39) over a curved deck (40) of which the fiber layers (W1, W2) are guided for joining them together. The second fiber layer (W2) is brought to the couch shoe (39) at an angle (α) of less than 20°, advantageously less than 15° in relation to the approach direction of the first fiber layer (W1). The couch shoe (39) is provided with underpressure and the radius of curvature of its deck (40) is usually larger than the radius of curvature of a guide roll (38) preceding it. By the couch shoe, the fiber layers can be joined together wetter than usual.
Patent FI-20106295-A0 (FI)
Inventor: VESTMAN HEIKKI
IPC: B23K/
Filed: 2010-12-07
Abstract: The invention relates to a narrow gap MIG/MAG welding torch (1) comprising means (2) for feeding filler wire (15) to the welding area, means (3, 4) for feeding cooling medium to the torch and means (5a, 5b) for feeding gas to the welding area. The torch (1) is made into an open construction, the body of which comprises essentially tubular filler wire feeding means (2), tubular cooling medium feeding means (3, 4), tubular shielding gas feeding means (5a, 5b), and at least one cross member (6, 7) connecting them. The tubular shielding gas supply means (5a, 5b) are located on the front and back with respect to the filler wire (15) feeding point, as seen in the direction of travel of the torch during welding, and constitute a structure which rigidifies the torch. At the weld area end of the tubular shielding gas feeding means (5a, 5b) is provided a gas nozzle (8) surrounding their heads, respectively. In the section inside the gas nozzle of the tubular shielding gas feeding means (5a, 5b) are formed gas discharge openings (10), which open away from the filler wire supply point. The gas nozzle (8) is provided with an aperture (9) which opens towards the filler wire feeding point, through which the gas flowing from the openings (10) of the tubular shielding gas feeding means (5a, 5b), guided by the inner walls of the gas nozzle (8) towards the filler wire feeding point, is discharged as an essentially laminar flow.
Patent IL-101388-A0 (IL)
Title: Process for the enzymatic preparation of macrolactone
IPC: C12R1/58
Filed: 1992-03-26
Abstract: The invention relates to a process for the enzymatic preparation of a polyunsaturated macrolactone of the group A streptogramins by means of a microorganism or an acellular preparation derived from this microorganism, capable of oxidising the 2-3 bond of the D-proline of macrolactones to dehydroproline.
Patent IL-102411-A0 (IL)
Title: Plastics tube head provided with a lining having a barrier effect
IPC: B29C65/42
Filed: 1992-07-03
Abstract: The subject of the invention is a tube head (1) having a barrier-effect inner coating (7), characterised in that this coating (7) consists of a multilayer polymeric element secured by an outer superficial layer (9) of the said element to the annular plastic covering (8) of the head (1), the said element (7) comprising moreover one or more polymeric barrier-effect layers (11) having a total thickness of between 0.008 and 0.05 mm and an inner superficial polyolefin or polyester layer (6). The subject of the invention is also the thermoformed single-piece part (7) which becomes this inner coating element. It is applicable to the manufacture of numerous tubes. <IMAGE>
Patent IL-103452-A0 (IL)
Title: T cell epitopes of the major allergens from dermatophagoides(house dust mite)
IPC: C12N15/09
Filed: 1992-10-16
Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
Patent IL-105822-A0 (IL)
Title: Treatment of tropical spastic paresis with peptide-t
IPC: C07K14/16
Filed: 1993-05-28
Abstract: Intranasal therapy using short peptides of the formula:    R<a>-Ser-Thr-Thr-Thr-Asn-Tyr-R<b>   where R<a> represents an amino terminal residue Ala- or D-Ala and R<b> represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II):    R<1>-R<2>-R<3>-R<4>-R<5>   (II> where R<1> is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-, Arg- or Glu-     R<2> is Thr, Ser or Asp     R<3> is Thr, Ser, Asn, Arg, Gln, Lys or Trp     R<4> is Tyr and R<5> is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful for intranasal administration in preventing viral infectivity in mammals by viruses which bind to the T4 receptors. These peptides are believed to act as completitive blocking agents.
Patent IL-106734-A0 (IL)
Title: Herbicidal 2-((4-heterocyclic-phenoxymethyl)phenoxy)alkanoates
IPC: C07D231/56
Filed: 1993-08-19
Abstract: Herbicidal compounds, compositions containing them, and a method for controlling weeds by application of the compositions are disclosed. The herbicidal compounds are 2-[(4-heterocyclic-phenoxymethyl)phenoxy]alkanoates of the formula   <IMAGE>   in which A is a derivative of an alkanoate bonded to the phenoxy oxygen at the alpha carbon, and Q is 4-difluoromethyl-4,5-dihydro-3-methyl-l,2,4-triazol-5(1H)-on-1-yl, 3,4,5,6-tetrahydrophthalimid-1-yl, 1-(1-methylethyl)imidazolidin-2,4-dion-3-yl, 1,4-dihydro-4-(3-fluoropropyl)-5H-tetrazol-5-on-1-yl, 3-chloro-4,5,6,7-tetrahydroindazol-2-yl, 4-methyl-l,2,4-triazine-3,5-dion-2-yl, 8-thia-1,6-diazabicyclo[4.3.0]-nonane-7-on-9-ylimino, or 1-methyl-6-trifluoromethyl-2,4-pyrimidinedione-3-yl; X is hydrogen, methyl, fluorine, or chlorine; Y is hydrogen; W is oxygen or sulfur; Z is hydrogen, fluorine, chlorine, bromine, lower alkyl, or methoxy; Z' is hydrogen, fluorine, or chlorine; and the group AO- may be in the 2, 3, or 4-position of the phenyl ring.
Patent IL-113558-A0 (IL)
Title: Method for manufacturing baked farinaceous foodstuffs
IPC: A21D15/00
Filed: 1995-05-01
Abstract: PCT No. PCT/GB95/00760 Sec. 371 Date Dec. 29, 1995 Sec. 102(e) Date Dec. 29, 1995 PCT Filed Apr. 3, 1995 PCT Pub. No. WO95/30333 PCT Pub. Date Nov. 16, 1995A method of manufacturing bread products comprises the sequential steps of subjecting dough pieces to baking, the baking conditions being such that the crumb of each piece is fully developed but not the crust thereof in order to obtain partially baked bread pieces; exposing the partially baked bread pieces to a vacuum cooling stage; and, after a delay, subjecting the partially baked bread pieces to further heating, whereby the crust is fully developed and baked bread products result.
Patent IL-123761-A0 (IL)
Title: Truncated glial cell line-derived neurotrophic factor
IPC: C07K14/52
Filed: 1996-09-16
Abstract: Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.
Patent IL-135853-A0 (IL)
Title: Chiral bisphosphinite ligands and methods utilizing the same
IPC: C07C45/64
Filed: 1998-11-12
Abstract: This invention is to develop novel transition metal catalysts for the pratical synthesis of important chiral molecules. The invention emphasizes asymmetric catalysis based on chiral bidentate phosphine ligands with cyclic ring structures which could be used to restrict conformational flexibility of the ligands and thus the efficiency of chiral transfer can be enhanced through the ligand rigidity.
Patent IL-136929-A0 (IL)
Title: Measurement of hydride using chemiluminescent acridinium compounds
IPC: C07D219/04
Filed: 1999-11-24
Abstract: The present invention discloses a method for the measurement of hydride using a chemiluminescent compound, such as an acridinium compound. The source of hydride for the reduction of acridinium compound may be of chemical or biochemical origin, or the result of enzymatic catalysis. The chemical source of hydride, might be NaBH4. A biochemical source of hydride might be that derived from NADH, or NADPH, while an enzymatic source would be the class of oxidoreductases termed dehydrogenases which convert NADH or NADPH from NAD or NADP. Among applications for acridinium compounds as chemiluminescent indicators of hydride are diagnostic assays using dehydrogenases as reagents, indicators, diagnostic markers or as labels. Ethanol, for example, might be detected with acridinium ester chemiluminescence through the reaction of alcohol dehydrogenase on ethanol, said reaction producing NADH. As a label, dehydrogenase might be used in an ELISA for the detection of a specific analyte with acridinium ester providing the signaling response.
Patent IL-137507-A0 (IL)
Title: Laser-scan process and device for guiding a missile to a target
IPC: F41G7/30
Filed: 2000-07-25
Abstract: The method of guiding a missile (M) to its target (T) involves using an observation field (5) in which the missile is guided. A missile guidance zone (8) is defined to localize the laser guidance area. The illumination of the laser beam coincides with the guidance zone. An Independent claim is included for a guidance system using the above method.
Patent IL-138658-A0 (IL)
Title: Chimeric protein
IPC: C12N1/15
Filed: 1998-03-31
Abstract: The present invention relates to a chimeric protein containing an intramolecular chaperone (IMC) like sequence linked to a target protein, preferably an insulin precursor. The present invention also relates to a process for obtaining a correctly folded insulin-precursor-contain chimeric protein, comprising, inter alia, contacting an incorrectly folded chimeric protein containing an IMC like sequence linked to an insulin precursor with at least one chaotropic auxiliary agent. The present invention further relates to an assay for screening an amino acid sequence for the ability to improve folding of an insulin precursor using a chimeric protein containing an IMC like sequence linked to an insulin precursor.
Patent IL-143839-A0 (IL)
Title: Cutting insert with chip control
IPC: B23B27/22
Filed: 1999-12-09
Abstract: An indexable cutting insert is disclosed capable of cutting operations over a wide range of depth of cuts. The insert has different geometries at different locations on the cutting surface such that, under differing cutting parameters, a desirable cutting surface will be in contact with the workpiece.
Patent IL-147157-A0 (IL)
Title: Method and system for notifying a caller that a cellular phone destination is available
Inventor: OKON SHMUEL
IPC: H04M3/42
Filed: 2000-06-15
Abstract: A method for connecting a caller (16) to a called destination (16) when the destination is initially unreachable comprises the steps of receiving in a communication network (14) a call origination from the caller to the unreachable destination, determining if the caller and destination are not busy and also are available to receive a call, and, when both are available and not busy, notifying the caller that the destination is available and subsequently making the connection. The system is particularly adapted for use with cellular networks wherein destination numbers are frequently unavailable because they are off, out of range, or due to insufficient network resources. The system does not rely upon cellular registration to determine if a destination is available but instead attempts to access the destination direction directly to ensure that the call can actually be completed before the caller is notified.
Patent IL-150978-A0 (IL)
Title: Nitroacridine/tumor inhibitor compositions
IPC: A61K31/56
Filed: 2001-02-16
Abstract: The invention is directed to 1-nitroacridine derivative(s)/tumor inhibitor(s) compositions as well as methods for using said compositions for inhibiting or preventing tumor growth, particularly, prostate cancer cell growth and metastases.
Patent IL-153530-A0 (IL)
Title: Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
IPC: C12N7/02
Filed: 2001-06-22
Abstract: Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift. In one embodiment, RSV glycoproteins are upregulated by shifting one or more glycoprotein-encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. A variety of additional mutations and nucleotide modifications are provided within the gene position-shifted RSV of the invention to yield desired phenotypic and structural effects.
Patent IL-158460-A0 (IL)
Title: METHOD FOR THE PREPARATION OF HIGHLY DENSIFIED SUPERCONDUCTOR MASSIVE BODIES OF MgB2
IPC: C04B35/58
Filed: 2002-05-10
Abstract: A method is described for the preparation of superconductor massive bodies of MgB<SUB>2</SUB>, having a density close to the theorical value, which comprises the following passages: mechanical activation of crystalline boron with the formation of activated powders; formation of a porous preform of said powders; assembly of the porous boron preform and massive precursors of metallic magnesium in a container and sealing thereof in an atmosphere of inert gas or with a low oxygen content; thermal treatment of the boron and magnesium as assembled above, at a temperature higher than 700° C. for a time greater than 30 minutes, with the consequent percolation of the magnesium, in liquid phase, through the activated crystalline boron powders.
Patent IL-159412-A0 (IL)
Title: A synergistic pharmaceutical combination for the prevention or treatment of diabetes
IPC: C07D213/82
Filed: 2002-07-10
Abstract: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.